{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T20:12:21Z","timestamp":1773000741126,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":83,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Anemia"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Very few trials of hydroxyurea efficacy and safety have been conducted in sub\u2010Saharan Africa. We aimed to evaluate the efficacy and safety of hydroxyurea and its utility in low\u2010resource settings.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We conducted a prospective comparative trial in patients with SCA. 128 patients were enrolled and divided into two groups. 68 patients were treated with hydroxyurea at a dose of 10\u201320\u2009mg\/kg\/day and 62 patients in a control group without hydroxyurea. The endpoints evaluated were feasibility, safety, and benefit (laboratory variables, sickle cell\u2013related events, transfusions).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The patients assigned to hydroxyurea treatment had a lower annual rate of crises than the control group (median 2.9 vs. 5.3 crises per year,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001), a lower annual rate of hospitalizations (median 2.2 vs. 4.7,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.002), and a lower annual rate of transfusions (median 1.3 vs. 5.1,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001). We observed a significant increase in Hb F from 11.77% to 14.6% (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.001) in patients treated with hydroxyurea. We also observed a significant increase in the mean Hb level from 7.3\u2009g\/dL to 9.2\u2009g\/dL in patients treated with hydroxyurea (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004). Patients treated with hydroxyurea also have a beneficial effect on WBC and platelet levels by reducing leukocytosis and thrombocytosis. The annual number of infectious complications was significantly lower in the group of patients treated with hydroxyurea.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Hydroxyurea has an important clinical benefit by reducing the incidence of vaso\u2010occlusive events, infections, and transfusions, which translates into fewer hospitalizations. The main problem is that it is not accessible to most of our patients who live in poor socioeconomic conditions.\n                  <\/jats:p>","DOI":"10.1155\/anem\/3576890","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T13:35:26Z","timestamp":1742909726000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Hydroxyurea in Patients With Sickle Cell Anemia in a Low\u2010Income Country (C\u00f4te d\u2019Ivoire)"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3994-5207","authenticated-orcid":false,"given":"Kouassi Gustave","family":"Koffi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Dieket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeraude","family":"N\u2019dhatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly Eloise","family":"Abenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis Dohoma","family":"Silu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boidy","family":"Kouakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danho Clotaire","family":"Nanho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"e_1_2_12_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)30193-9"},{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199709113371107"},{"key":"e_1_2_12_3_2","unstructured":"https:\/\/www.afro.who.int\/publications\/who-sickle-package-intervention-sickle-cell-disease-management. WHO sickle package of interventions for sickle cell disease management | WHO | Regional Office for Africa."},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61229-x"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199505183322001"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1645"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2007.09.013"},{"key":"e_1_2_12_8_2","article-title":"Hydroxyurea for Children with Sickle Cell Anemia in Sub-saharan Africa","author":"Tshilolo L.","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27816"},{"key":"e_1_2_12_10_2","unstructured":"BrunM. BourdoulousS. andCouraudP. O. Effect of Hydroxyurea on Endothelial Cells in Culture 25th Annual Meeting of the National Sickle Cell Program April 2001 New York NY."},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0333"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199801000-00004"},{"key":"e_1_2_12_13_2","first-page":"62","article-title":"Experimental Therapy for Sickle Cell Disease: Use of Hydroxyurea","volume":"16","author":"Charache S.","year":"1994","journal-title":"American Journal of Pediatric Hematology Oncology"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830500211"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_3447_21"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v112.11.2477.2477"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-3101(24)00238-x"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0268-960x(02)00074-7"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27214"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14138"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.9.2878"},{"key":"e_1_2_12_22_2","unstructured":"KoffiK. G. DieketR. N\u2019dhatzE.et al. Efficacy of Hydroxyurea in Patients with Sickle Cell Anaemia in a Low-Income Country (C\u00f4te d\u2019Ivoire)."}],"container-title":["Anemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/anem\/3576890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/anem\/3576890","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/anem\/3576890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:44:55Z","timestamp":1772991895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/anem\/3576890"}},"subtitle":[],"editor":[{"given":"Duran","family":"Canatan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/anem\/3576890"],"URL":"https:\/\/doi.org\/10.1155\/anem\/3576890","archive":["Portico"],"relation":{},"ISSN":["2090-1267","2090-1275"],"issn-type":[{"value":"2090-1267","type":"print"},{"value":"2090-1275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"3576890"}}